Authors: Nasirzadeh, Mahdieh
Rasmi, Yousef
Rahbarghazi, Reza
Kheradmand, Fatemeh
Karimipour, Mojtaba
Aramwit, Pornanong
Astinfeshan, Maryam
Gholinejad, Zafar
Daeihasani, Behrokh
Saboory, Ehsan
Shirpoor, Alireza
Rezabakhsh, Aysa
Zolali, Elmira
Khalaji, Naser
Title: Crocetin promotes angiogenesis in human endothelial cells through PI3K-Akt-eNOS signaling pathway
Language (ISO): en
Abstract: Previous studies proved the pro-angiogenic effect of Crocetin, a natural carotenoid dicarboxylic acid, in both in vivo and in vitro models. However, the exact mechanism of Crocetin action has not completely been elucidated yet. The current experiment was designed to find the activity of PI3K-Akt-eNOS axis after the treatment of endothelial cells with Crocetin in vitro. Human Umbilical Vein Endothelial Cells (HUVECs) were incubated with various concentrations of Crocetin (1, 5, 25, 50, and 100 μM) over a period of 72 h. Crocetin significantly increased HUVECs viability after 72 h as compared with the control group. We also found that Crocetin promoted the formation of the capillary-like structure compared to the control (p<0.05). Moreover, an improved migration rate and increased MMP-9 activity were observed in HUVECs that received 50 μM Crocetin (p<0.05). Crocetin enhanced the uptake of Ac-LDL which is correlated with increased lipid metabolism. Based on the data from thecurrent experiment, protein level of VEGFR-1, -2 and p-Akt/Akt, p-eNOS/eNOS ratios were increased 72 h after the treatment of HUVECs with Crocetin (p<0.05). In contrast, the transcription level of VEGF was reduced in Crocetin-treated cells. These data demonstrated that Crocetin promotes HUVECs angiogenesis potential by the modulation of VEGF signaling pathway and increased cell viability. The PI3K/Akt/eNOS axis is required for a Crocetin-associated activity in endothelial cells.
Subject Headings: Crocetin
Human endothelial cells
Tube formation
VEGFR-2-Akt-eNOS signaling
Issue Date: 2019-10-21
Rights link:
Appears in Collections:Original Articles

Files in This Item:
File Description SizeFormat 
Rasmi_21102019_proof.pdfDNB1.33 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons